fingolimod hydrochloride has been researched along with risperidone in 2 studies
| Studies (fingolimod hydrochloride) | Trials (fingolimod hydrochloride) | Recent Studies (post-2010) (fingolimod hydrochloride) | Studies (risperidone) | Trials (risperidone) | Recent Studies (post-2010) (risperidone) |
|---|---|---|---|---|---|
| 2,771 | 157 | 2,062 | 6,924 | 1,505 | 2,477 |
| Protein | Taxonomy | fingolimod hydrochloride (IC50) | risperidone (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.015 | |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.0027 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.0097 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 5.2734 | |
| Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | 4.1901 | |
| D(2) dopamine receptor | Homo sapiens (human) | 0.0167 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.0991 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.026 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.0096 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.799 | |
| D(1A) dopamine receptor | Homo sapiens (human) | 0.479 | |
| Histamine H2 receptor | Homo sapiens (human) | 1.483 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.01 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.0016 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.0057 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.799 | |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.0027 | |
| 5-hydroxytryptamine receptor 2C | Mus musculus (house mouse) | 0.0015 | |
| Alpha-1A adrenergic receptor | Homo sapiens (human) | 0.0105 | |
| 5-hydroxytryptamine receptor 2A | Mus musculus (house mouse) | 0.0015 | |
| Histamine H1 receptor | Homo sapiens (human) | 0.4515 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.024 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.023 | |
| D(2) dopamine receptor | Mus musculus (house mouse) | 0.023 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.0154 | |
| 5-hydroxytryptamine receptor 2B | Mus musculus (house mouse) | 0.0015 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 0.6303 | |
| 5-hydroxytryptamine receptor 1A | Mus musculus (house mouse) | 0.43 | |
| Nuclear receptor subfamily 3 group C member 3 | Bos taurus (cattle) | 4.1901 | |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | 1.6 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berger, JR; Espinosa, PS | 1 |
| Akhondzadeh, S; Amanollahi, M; Ardakani, MK; Basti, FA; Jameie, M; Karbalaee, M; Mokhtari, S; Moradi, K; Parsaei, M; TaghaviZanjani, F | 1 |
1 trial(s) available for fingolimod hydrochloride and risperidone
| Article | Year |
|---|---|
Efficacy and safety of adjunctive therapy with fingolimod in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial.
Topics: Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Fingolimod Hydrochloride; Humans; Risperidone; Schizophrenia; Treatment Outcome | 2023 |
1 other study(ies) available for fingolimod hydrochloride and risperidone
| Article | Year |
|---|---|
Delayed fingolimod-associated asystole.
Topics: Administration, Oral; Antipsychotic Agents; Bradycardia; Electrocardiography; Fingolimod Hydrochloride; Heart Arrest; Humans; Immunosuppressive Agents; Male; Multiple Sclerosis; Propylene Glycols; Risperidone; Sphingosine; Time Factors; Young Adult | 2011 |